TEAD inhibitors target a specific signaling pathway, known as the Hippo pathway, that controls organ development and tissue growth and regeneration. This pathway is genetically altered in up to 10% of cancers. Such genetic mutations are key drivers in several tumor types, including certain types of mesotheliomas, non-small cell lung cancer, head and neck cancer and kidney cancer.
CD3 and VIB have already generated promising preclinical data on the portfolio of TEAD inhibitors. SpringWorks is very pleased to expand its portfolio with the in-licensing of these selective and potent inhibitors.